Kristen M. Weishaar

Combination of Hypofractionated Radiation Therapy and Gilvetmab for the Treatment of Cutaneous or Subcutaneous Mast Cell Tumours in Dogs

Tiffany Wormhoudt Martin, Douglas H. Thamm, Kristen M. Weishaar

Gilvetmab is a caninised monoclonal antibody against canine PD-1. Concurrent or sequential administration of anti-PD-1 antibodies and radiation therapy (RT) improves survival time in various species. Eighteen dogs with mast cell tumours (MCTs) were prospectively treated with 24 Gy of RT over …

us (code pays fourni par la source)

Impacts of Vincristine and Prednisolone Chemotherapy on the Canine Gut Microbiota in Dogs Undergoing Treatment for Lymphoma

Juan Antonio Aragón Moreno, Annika M. Weber, Madison Tipton, Jennifer Marie Thomsen et autres

Chemotherapy can have adverse gastrointestinal effects in dogs and people. The objective of this study was to assess the impact of vincristine and prednisolone/prednisone, as part of a CHOP chemotherapy [cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine) and prednisolone/prednisone] protocol, on gastrointestinal dysbiosis in dogs …

us, Égypte (code pays fourni par la source)

Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2

Nicola J. Mason, Laura Elizabeth Selmic, Audrey Ruple, Cheryl A. London et autres

A clinical trial in dogs with spontaneous osteosarcoma was performed to assess a recombinant Listeria expressing a chimeric human HER2 (ADXS31-164 c ) as an adjunctive vaccine strategy to prevent metastatic disease and determine immunological correlates of clinical outcome. A total of …

us, ca, au (code pays fourni par la source)

A Practical Guide to Clinical Studies in Veterinary Oncology

Kristen M. Weishaar, Kai‐Biu Shiu, Zachary M. Wright

us (code pays fourni par la source)

Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma

Jacob M. Siewert, Daniel L. Gustafson, Kristen M. Weishaar, Annie Galloway et autres

BACKGROUND: This study was performed to determine the ability to escalate drug doses in a 15-week CHOP protocol in dogs with multicentric lymphoma. HYPOTHESIS: We hypothesized that at least 50% of dogs could successfully be escalated in at least 1 drug. Secondary …

us (code pays fourni par la source)

Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma

Laura Vari Ashton, Kristen M. Weishaar, Bernard Séguin, Amy L. MacNeill

Human rhabdomyosarcomas are rarely cured by surgical resection alone. This is also true for high-grade soft tissue sarcomas in dogs. Dogs with spontaneous sarcoma are good models for clinical responses to new cancer therapies. Strategic combinations of immunotherapy and oncolytic virotherapy (OV) …

us (code pays fourni par la source)

Oclacitinib and Myxoma Virus Therapy in Dogs with High Grade Soft Tissue Sarcoma

Laura Vari Ashton, Kristen M. Weishaar, Bernard Séguin, Amy L. MacNeill

Human rhabdomyosarcomas are rarely cured by surgical resection alone. This is also true for high grade soft tissue sarcomas in dogs. Dogs with spontaneous sarcoma are good models for clinical responses to new cancer therapies. Strategic combinations of immunotherapy and oncolytic virotherapy …

us, ca (code pays fourni par la source)

A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

Dylan T. Ammons, R. Adam Harris, Leone S. Hopkins, Jade N. Kurihara et autres

Translationally relevant animal models are essential for the successful translation of basic science findings into clinical medicine. While rodent models are widely accessible, there are numerous limitations that prevent the extrapolation of findings to human medicine. One approach to overcome these limitations …

us (code pays fourni par la source)

Single cell RNA sequencing analysis of tumor responses to triple drug oral immunotherapy in dogs with osteosarcoma

Dylan T. Ammons, Jade N. Kurihara, Kristen M. Weishaar, Heather L. Gardner et autres

Abstract Osteosarcoma constitutes a rare childhood cancer that is associated with dismal outcomes. As such, there is a need to develop non-invasive immunotherapeutic approaches to treat this aggressive malignancy. To address this need, we described the cellular heterogeneity in spontaneously occurring canine …

us (code pays fourni par la source)

Supplementary Data from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Jenna H. Burton, Christina N. Mazcko, Amy Kathleen LeBlanc, Joseph M. Covey et autres

All supplementary files together

Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Fig. 2 shows the walk-in pharmacokinetics, both measured results and simulated values, for dogs treated with oral sirolimus in preparation for the definitive adjuvant trial.

Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus